CLINICAL TRIALS PROFILE FOR FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

505(b)(2) Clinical Trials for FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Dosage	NCT02372357 ↗	A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area	Completed	Institutul Clinic Fundeni	Phase 4	2012-02-01	A new prophylactic posaconazole dosing regimen of 120mg/m² tid is evaluated pharmacologically in children 13 years and younger, suffering from a hematologic malignancy.
New Dosage	NCT02372357 ↗	A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area	Completed	Institutul Clinic Fundeni Bucharest	Phase 4	2012-02-01	A new prophylactic posaconazole dosing regimen of 120mg/m² tid is evaluated pharmacologically in children 13 years and younger, suffering from a hematologic malignancy.
New Dosage	NCT02372357 ↗	A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area	Completed	Universitaire Ziekenhuizen Leuven	Phase 4	2012-02-01	A new prophylactic posaconazole dosing regimen of 120mg/m² tid is evaluated pharmacologically in children 13 years and younger, suffering from a hematologic malignancy.
New Indication	NCT04495608 ↗	Fluconazole in Hypercalciuric Patients With Increased 1,25(OH)2D Levels	Recruiting	Hospices Civils de Lyon	Phase 2	2021-01-13	Hypercalciuria is one of the most frequent metabolic disorders associated with nephrolithiasis and/or nephrocalcinosis leading to Chronic Kidney Disease (CKD) and bone complications in adults. Hypercalciuria can be secondary to increased intestinal absorption and/or increased renal distal tubular reabsorption of calcium due to increased active vitamin D, i.e. 1,25(OH)2D, levels. The management of hypercalciuria is challenging. Classic management based on hyperhydration and dietary advice has low impact on calciuria and therefore on CKD progression. Other strategies such as hydrochlorothiazide can be proposed, however with an uncertain medical benefit in view of side effects (hypokalemia, asthenia, potential cutaneous long-term side effects). Azoles are known to inhibit the 1α-hydroxylase and therefore decrease 1,25(OH)2D levels. These antifungal drugs are commonly used in neonates, infants and adults; pharmacokinetic data are well described. Recently, to improve azoles tolerance, fluconazole has been successfully reported to reduce calciuria in patients with CYP24A1 mutation (1 adult) or NPTIIc mutations (1 child), while maintaining a stable renal function. Based on these observations, the investigators hypothesize that fluconazole is effective to decrease and normalize calciuria in patients with hypercalciuria and increased 1,25(OH)2D levels. The primary objective is to demonstrate that fluconazole normalizes or decreases calciuria after 4 months of treatment in patients with hypercalciuria and increased 1,25(OH)2D levels. The secondary objectives aim to describe: - the effects of fluconazole on the evolution over time of the calcium/phosphate metabolism, - the evolution of renal function, - the cohort at Baseline and after 4 months of treatment period, - the safety of fluconazole, - the onset of potential mycological resistances, - and the treatment compliance. This is a prospective, interventional, national, randomized in 2 parallel groups (1:1), controlled versus placebo, double blind trial. This study will involve patients between 10 and 50 years of age suffering from nephrolithiasis and/or nephrocalcinosis with hypercalciuria (> 0.1 mmol/kg/d) and increased 1,25 (OH)2D levels (≥ 150 pmol/l) and 25-OH-D levels (≥50 nmol/L). FLUCOLITH study is a unique opportunity to develop a new indication of a well-known and not expensive drug (e.g. fluconazole) in rare renal diseases, the ultimate objective being the secondary prevention of CKD worsening in these patients. If the results of this proof-of-concept randomized controlled trial are positive, the investigators will propose an extension phase to evaluate the long term efficacy and safety of fluconazole on renal and bone parameters.
OTC	NCT05059145 ↗	A Clinical Trial for Chlorhexidine as Treatment for Vulvovaginal Candidiasis	Not yet recruiting	Karolinska Institutet	Phase 2	2021-10-01	The overall aim of this study is to investigate if vaginally applied 1% chlorhexidine gluconate (CHG) could be an alternative treatment to oral fluconazole (FLZ), both during an acute episode and as prophylaxis, against recurrent infections of vulvovaginal candidiasis (RVVC). RVVC is very common in fertile women. Up to six months of treatment with FLZ is recommended for RVVC. Over the last ten years, the use of FLZ has increased markedly in many countries. No major problems have been noted with resistance development, but there is concern that this will occur in the future and alternative treatments are requested. In recent years, it has emerged that flukonazol interacts with several different types of drugs that are common in the patient group; several antidepressants, pain relief at dysmenorrhea (NSAID) and oral contraceptives to name a few. In Sweden an over-the-counter vaginal cream consisting of 1% chlorhexidine gluconate (Hibitane®) is available with the indication antiseptic use in vaginal examinations, especially during childbirth. The product has been used for a long time in various gynecological and obstetric surgical procedures. Hibitane® is approved during pregnancy and the cream is usually well tolerated. Our research group has previously done an in vitro study in which we analyzed the effect of FLZ and CHG's ability to kill fungal cells and to break down existing biofilm or prevent new biofilm formation. The biofilm formation is an important stage for the fungal cells to attach to surfaces such as skin and mucosa and is considered a first step in the development of an infection. In the biofilm, the fungus can hide from the immune system and also to some extent for various treatments aimed against the fungus. The results of the study showed that CHG was better than FLZ both at killing the fungal cells and preventing new biofilm from forming and dissolving already established "old" biofilm. This effect is absolutely crucial for successful treatment with antimycotics. These encouraging results form the basis of the planned study. If CHG is at least as effective as FLZ with little impact on vaginal lactobacillus, with high tolerability and without cytotoxic effect on epithelial cells, the results of the study might lead to major benefits to the patients with reduced risk of systemic side effects such as drug interactions, development of drug resistance and reduced drug costs.

All Clinical Trials for FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000627 ↗	Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome	Completed	Pfizer	N/A	1969-12-31	To evaluate the use of fluconazole as (1) induction therapy in histoplasmosis, (2) maintenance therapy to prevent relapse of histoplasmosis. Histoplasmosis is a serious opportunistic infection in patients with AIDS. Fluconazole is a triazole antifungal agent that has been used successfully in the treatment of experimental histoplasmosis in animals, but has not been completely evaluated in patients for this use. It has been approved by the Food and Drug Administration for certain other fungal infections. Nevertheless, physicians are prescribing it to their patients with histoplasmosis. This is a pilot study to examine the role of fluconazole for treating histoplasmosis in AIDS patients.
NCT00000627 ↗	Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	To evaluate the use of fluconazole as (1) induction therapy in histoplasmosis, (2) maintenance therapy to prevent relapse of histoplasmosis. Histoplasmosis is a serious opportunistic infection in patients with AIDS. Fluconazole is a triazole antifungal agent that has been used successfully in the treatment of experimental histoplasmosis in animals, but has not been completely evaluated in patients for this use. It has been approved by the Food and Drug Administration for certain other fungal infections. Nevertheless, physicians are prescribing it to their patients with histoplasmosis. This is a pilot study to examine the role of fluconazole for treating histoplasmosis in AIDS patients.
NCT00000639 ↗	A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis	Completed	Washington University School of Medicine	N/A	1969-12-31	To evaluate the effectiveness and safety of amphotericin B plus flucytosine (5-fluorocytosine) compared to amphotericin B alone for a first episode of acute cryptococcal meningitis in AIDS patients, and to compare the effectiveness and safety of fluconazole versus itraconazole. At least 10 percent of patients with a low CD4 count and HIV infection will develop meningitis due to Cryptococcus neoformans. More effective treatments than the standard therapy need to be explored.
NCT00000639 ↗	A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	To evaluate the effectiveness and safety of amphotericin B plus flucytosine (5-fluorocytosine) compared to amphotericin B alone for a first episode of acute cryptococcal meningitis in AIDS patients, and to compare the effectiveness and safety of fluconazole versus itraconazole. At least 10 percent of patients with a low CD4 count and HIV infection will develop meningitis due to Cryptococcus neoformans. More effective treatments than the standard therapy need to be explored.
NCT00000676 ↗	Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081)	Completed	Pfizer	Phase 3	1969-12-31	To study the effectiveness, safety, and tolerance of fluconazole versus clotrimazole troches (lozenges) as prophylaxis (preventive treatment) against fungal infections in patients enrolled in ACTG 081 (a study of prophylaxis against pneumocystosis, toxoplasmosis, and serious bacterial infection). Primarily, to compare the rates of invasive infections by C. neoformans, endemic mycoses, and Candida. To compare the mortality rates due to fungal infections between two antifungal prophylactic treatments. Secondarily, to assess the effect of prophylaxis on the incidence of severe fungal infections, defined as invasive infections and esophageal candidiasis and less severe mucocutaneous infection. Serious fungal infections are significant complicating and life-threatening occurrences in patients with advanced HIV infection. Oropharyngeal candidiasis is found in almost all such patients, and causes pain, difficulty in swallowing, and loss of appetite. Similarly, esophageal candidiasis causes illness in the population. Cryptococcosis, endemic mycoses, and coccidioidomycosis also cause significant illness and death in AIDS patients. Once established, fungal infections in AIDS patients generally require continuous suppressive therapy because attempts at curing these infections are usually unsuccessful. Fluconazole has a number of characteristics that would make it a logical candidate to examine as a prophylactic agent in patients with advanced HIV infection. Animal studies have shown it to be prophylactic in models of candidiasis, cryptococcosis, histoplasmosis, and coccidioidomycosis. Initial experience in patients with active cryptococcal meningitis appears favorable, and studies of oropharyngeal candidiasis show it to be effective.
NCT00000676 ↗	Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081)	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	1969-12-31	To study the effectiveness, safety, and tolerance of fluconazole versus clotrimazole troches (lozenges) as prophylaxis (preventive treatment) against fungal infections in patients enrolled in ACTG 081 (a study of prophylaxis against pneumocystosis, toxoplasmosis, and serious bacterial infection). Primarily, to compare the rates of invasive infections by C. neoformans, endemic mycoses, and Candida. To compare the mortality rates due to fungal infections between two antifungal prophylactic treatments. Secondarily, to assess the effect of prophylaxis on the incidence of severe fungal infections, defined as invasive infections and esophageal candidiasis and less severe mucocutaneous infection. Serious fungal infections are significant complicating and life-threatening occurrences in patients with advanced HIV infection. Oropharyngeal candidiasis is found in almost all such patients, and causes pain, difficulty in swallowing, and loss of appetite. Similarly, esophageal candidiasis causes illness in the population. Cryptococcosis, endemic mycoses, and coccidioidomycosis also cause significant illness and death in AIDS patients. Once established, fungal infections in AIDS patients generally require continuous suppressive therapy because attempts at curing these infections are usually unsuccessful. Fluconazole has a number of characteristics that would make it a logical candidate to examine as a prophylactic agent in patients with advanced HIV infection. Animal studies have shown it to be prophylactic in models of candidiasis, cryptococcosis, histoplasmosis, and coccidioidomycosis. Initial experience in patients with active cryptococcal meningitis appears favorable, and studies of oropharyngeal candidiasis show it to be effective.

Clinical Trial Conditions for FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

Condition Name

Condition Name for FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER
Intervention	Trials
HIV Infections	42
Candidiasis	21
Mycoses	19
Meningitis, Cryptococcal	16

Condition MeSH

Condition MeSH for FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER
Intervention	Trials
Candidiasis	77
Mycoses	45
HIV Infections	45
Infections	31

Clinical Trial Locations for FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

Trials by Country

Trials by Country for FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER
Location	Trials
United States	771
China	36
Canada	28
Spain	20
Belgium	15

Trials by US State

Trials by US State for FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER
Location	Trials
California	57
Texas	55
Florida	46
New York	46
Pennsylvania	40

Clinical Trial Progress for FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
PHASE4	6
PHASE3	4
PHASE2	4

Clinical Trial Status

Clinical Trial Status for FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Completed	189
Recruiting	28
Unknown status	21

Clinical Trial Sponsors for FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER
Sponsor	Trials
Pfizer	40
National Institute of Allergy and Infectious Diseases (NIAID)	25
Merck Sharp & Dohme Corp.	7

Sponsor Type

Sponsor Type for FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER
Sponsor	Trials
Other	231
Industry	168
NIH	46

Fluconazole in Dextrose 5% in Plastic Container: Clinical Trials, Market Analysis, Patent Status and 2030 Projection

Last updated: August 1, 2026

Fluconazole in 5% dextrose injection is a mature, genericized intravenous antifungal product used primarily in hospitals for candidiasis and cryptococcosis. Its active pharmaceutical ingredient has no meaningful compound-patent protection remaining in the United States. Commercial competition is driven by manufacturing reliability, hospital contracts, availability of ready-to-use bags, pharmacy labor savings and shortages rather than clinical differentiation.

The market is expected to grow at a low single-digit rate through 2030, supported by persistent invasive fungal infections, oncology and transplant care, and demand for premixed intravenous products. Price erosion and substitution by oral fluconazole, echinocandins and liposomal amphotericin B will limit revenue growth.

What is fluconazole in dextrose 5% injection?

Fluconazole in dextrose 5% is an intravenous solution containing fluconazole diluted in 5% dextrose injection. Commercial products generally contain fluconazole at a concentration of 2 mg/mL.

Product attribute	Typical specification
Active ingredient	Fluconazole
Dosage form	Intravenous solution
Diluent	5% dextrose in water
Typical concentration	2 mg/mL
Common bag strengths	100 mg/50 mL, 200 mg/100 mL, 400 mg/200 mL
Administration	Intravenous infusion
Major indications	Candidemia, disseminated candidiasis, cryptococcal meningitis, mucosal candidiasis
Primary customers	Hospitals, health systems, group purchasing organizations and specialty distributors
Regulatory status	FDA-approved generic and reference-product presentations
Patent position	Compound and core-use protection expired

The product is distinct from oral fluconazole capsules, tablets and suspension, although all contain the same active ingredient. Intravenous fluconazole is used when oral administration is not possible or when clinicians require parenteral therapy.

What clinical trials support fluconazole injection?

Fluconazole’s clinical evidence base was established through randomized and comparative studies conducted before and after the original Diflucan approvals. New clinical trials are generally conducted for new indications, populations or treatment strategies rather than to re-establish the efficacy of a generic premixed bag.

FDA-approved clinical uses

The FDA label identifies intravenous fluconazole for treatment of:

• Candidemia and disseminated Candida infections.
• Candida urinary tract infections and peritonitis.
• Esophageal and oropharyngeal candidiasis.
• Cryptococcal meningitis.
• Prophylaxis against Candida infections in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy or radiation therapy.[1]

Fluconazole is fungistatic against most Candida species and has activity against Cryptococcus neoformans. It does not provide reliable coverage against molds such as Aspergillus.

Current clinical-trial relevance

The current clinical-trial profile is shaped by resistance and disease severity.

Clinical area	Role of fluconazole	Trial and market implication
Uncomplicated mucosal candidiasis	Established treatment	Limited need for new product-specific trials
Candidemia	Step-down or selected initial therapy	Echinocandins are often preferred for unstable patients or suspected resistant species
Cryptococcal meningitis	Used in combination regimens and consolidation or maintenance therapy	Global public-health trials continue to evaluate shorter and lower-cost regimens
Neonatal and pediatric candidiasis	Important off-label and label-supported use depending on population	Dosing and safety studies remain relevant
Candida auris	Generally unreliable because of frequent resistance	Reduces addressable demand in resistant hospital outbreaks
Antifungal prophylaxis	Used selectively	Competition from mold-active azoles and echinocandins

The 2016 Infectious Diseases Society of America guideline remains a major clinical reference for candidiasis management. It recommends an echinocandin as initial therapy for most adults with candidemia, with transition to fluconazole when the patient is clinically stable, the isolate is susceptible and blood cultures have cleared.[2]

The 2022 World Health Organization guideline for cryptococcal disease supports shorter, more accessible antifungal regimens in resource-limited settings. These protocols can increase demand for fluconazole, although much of that demand is oral rather than intravenous.[3]

Are new clinical trials testing fluconazole in dextrose 5% bags?

No major clinical-development program is required for the premixed generic bag itself. The product does not contain a new molecular entity, new mechanism or novel delivery system. Trial activity involving fluconazole generally evaluates:

• Combination therapy for cryptococcal meningitis.
• Treatment duration and dosing in patients with HIV.
• Pediatric and neonatal pharmacokinetics.
• Step-down treatment for candidemia.
• Antifungal stewardship and de-escalation.
• Management of resistant Candida species.

These studies affect utilization but do not create new exclusivity for the plastic-container presentation.

What is the FDA regulatory status of fluconazole in dextrose 5%?

Fluconazole injection is approved under the FDA’s abbreviated new drug application pathway when the generic product demonstrates pharmaceutical equivalence, bioequivalence where applicable and quality comparable to the reference product.

The reference product is Pfizer’s Diflucan. The original product was approved under NDA 019949. Generic manufacturers have marketed fluconazole injection in multiple presentations, including dextrose-containing premixed bags and products requiring pharmacy dilution.

The FDA label identifies warnings and precautions involving:

• Hepatotoxicity.
• QT prolongation and torsade de pointes risk.
• Clinically important drug interactions through CYP2C9, CYP2C19 and CYP3A4 inhibition.
• Dose adjustment in renal impairment.
• Fetal harm risk with chronic high-dose exposure during pregnancy.
• Selection of resistant Candida species.

The intravenous product must be administered at a controlled infusion rate. The dextrose vehicle makes the product ready to administer but creates storage, handling and compatibility requirements. Product-specific labeling controls the allowable temperature range, container integrity, infusion conditions and beyond-use practices.[1]

What patents protect fluconazole injection?

The original fluconazole compound patent has expired. The core patent was U.S. Patent No. 4,404,216, assigned to Pfizer-related entities and directed to triazole antifungal compounds including fluconazole.[4] Its enforceable term ended years ago.

Fluconazole patent timeline

Patent or right	Subject matter	Status
U.S. Patent No. 4,404,216	Fluconazole compound and related triazoles	Expired
Original Diflucan exclusivity	New chemical entity and NDA-based protection	Expired
Original formulation and labeling rights	Product-specific formulation and approved uses	Expired or commercially non-blocking
Generic injectable approvals	ANDA rights	Active only for individual approved products
Container and manufacturing know-how	Bag construction, sterilization, filling and packaging	May remain proprietary but does not create broad market exclusivity

The principal barriers are regulatory quality and manufacturing capability, not patent blocking rights. A manufacturer still must demonstrate control of sterility, particulate matter, extractables and leachables, container closure integrity, stability and infusion performance.

What Orange Book status applies to fluconazole injection?

The Orange Book lists approved drug products and patent or exclusivity information associated with FDA-approved applications. Fluconazole injection is generally treated as an established generic product category rather than an active patent-protected franchise.

Paragraph IV challenges

Paragraph IV litigation risk is low for the core fluconazole injection market because the fundamental composition-of-matter and principal use patents expired long ago. New Paragraph IV disputes would more likely concern:

• A newly listed formulation patent.
• A specific container or presentation.
• A later-approved use.
• A pediatric formulation.
• A manufacturing process patent with a narrow claim scope.

Those risks do not normally affect ordinary 2 mg/mL fluconazole in 5% dextrose bags already approved through ANDAs.

Generic launch risk

Generic launch risk is asymmetric:

• Entry risk is high because the market is technically mature and patent barriers are weak.
• Commercial launch risk is also high because hospitals buy through tenders and contracts.
• Supply-chain risk is material because sterile injectable manufacturing capacity is concentrated.
• Price risk is high when several suppliers compete for the same hospital contracts.

Which companies compete in fluconazole injection?

Competition varies by country and by bag configuration. Major or historically important suppliers include Pfizer, Baxter, Fresenius Kabi, Hikma, Sagent Pharmaceuticals, and other regional generic injectable manufacturers.

Company group	Competitive position
Pfizer	Reference-brand heritage through Diflucan; limited ability to maintain premium pricing in generic injectable tenders
Baxter	Strong hospital distribution and premixed intravenous-container capability
Fresenius Kabi	Broad generic injectable portfolio and institutional sales infrastructure
Hikma	Established generic injectable manufacturing and hospital presence
Sagent and regional manufacturers	Contract-driven participation, often focused on shortage opportunities and tender pricing
Contract manufacturers	Supply private-label products for distributors and health systems

The decisive differentiators are supply continuity, FDA compliance, manufacturing redundancy, national distribution and contract economics. Clinical differentiation is limited.

How large is the fluconazole injection market?

Public company filings generally do not report revenue for fluconazole in dextrose 5% as a standalone product. Market estimates therefore require a bottom-up model based on hospital injectable antifungal utilization, average selling prices, product mix and regional generic penetration.

A reasonable global market framework is:

Segment	2024 estimated market position	2030 outlook
United States hospital IV fluconazole	Mature, low-growth generic segment	Low single-digit value growth or flat value
Europe	Mature generic and tender market	Stable unit demand, continued price pressure
Japan and other developed Asia	Established hospital use	Low growth
China and India	Higher unit growth, lower prices	Mid-single-digit unit growth
Latin America, Middle East and Africa	Underpenetrated but price-sensitive	Higher percentage growth from a small base

On a global basis, the addressable market for injectable fluconazole products, including premixed dextrose presentations and concentrate or diluted formats, is likely in the low hundreds of millions of dollars annually rather than the multi-billion-dollar range associated with newer systemic antifungal classes. The premixed 5% dextrose bag represents only a portion of that market.

Market projection, 2024-2030

Scenario	2024-2030 unit CAGR	2024-2030 value CAGR	Main drivers
Base case	2%-3%	0%-2%	Stable hospital use offset by price erosion
Upside case	4%-5%	2%-4%	Injectable shortages, expanded hospital access and higher fungal burden
Downside case	0%-1%	-2% to 0%	Greater echinocandin use, oral substitution and aggressive tender pricing

The base case is the most commercially defensible. Volume can rise while revenue remains flat because generic hospital injectables experience annual price compression.

What drives demand for fluconazole in dextrose bags?

Demand is linked to hospital admissions and treatment protocols rather than consumer behavior.

Principal demand drivers

1. Invasive candidiasis in intensive-care, oncology and transplant populations.
2. Growth in central venous catheter use and complex inpatient care.
3. Expansion of hospital capacity in emerging markets.
4. Demand for ready-to-use products that reduce pharmacy compounding.
5. Antifungal stewardship programs that use fluconazole as step-down treatment.
6. Procurement preferences for products with reliable supply and standardized bag sizes.

Principal demand constraints

1. Increasing first-line use of echinocandins for severe candidemia.
2. Rising fluconazole resistance among Candida glabrata and Candida auris.
3. Conversion from intravenous to oral therapy once patients stabilize.
4. Lower utilization in patients requiring mold-active coverage.
5. Hospital purchasing pressure and generic price erosion.
6. Reduced use where oral fluconazole is clinically appropriate.

How does fluconazole compare with competing antifungals?

Product class	Examples	Advantages over IV fluconazole	Disadvantages
Echinocandins	Micafungin, caspofungin, anidulafungin	Stronger initial positioning for invasive candidiasis and resistant species	Higher cost; IV-only; limited urinary and central nervous system penetration
Polyenes	Liposomal amphotericin B	Broad activity, including many resistant fungi	Nephrotoxicity, infusion reactions and high acquisition cost
Triazoles	Voriconazole, posaconazole, isavuconazole	Mold activity and expanded spectrum	More complex interactions, monitoring and higher cost
Fluconazole	IV or oral	Low cost, predictable pharmacology, oral step-down option	Limited mold activity and resistance concerns

Fluconazole remains competitive where the Candida isolate is susceptible, the patient is stable and clinicians prioritize cost control or transition to oral treatment.

What manufacturing and intellectual-property barriers affect the market?

Manufacturing is the main barrier to entry. Fluconazole itself is a relatively established active ingredient, but sterile intravenous production requires validated aseptic processing and container systems.

Key manufacturing risks

• Dependence on a limited number of active-ingredient suppliers.
• Sterile filling capacity constraints.
• Container-closure failures.
• Particulate contamination and product recalls.
• Degradation or interaction with plastic materials.
• Dextrose-related stability and sterilization controls.
• FDA inspection findings.
• Regional shortages of ready-to-use bags.

Plastic-container products also require evaluation of leachables, extractables, sorption and compatibility with administration sets. These requirements can delay approval or increase post-approval manufacturing costs even when no blocking patent exists.

What litigation and settlement agreements affect fluconazole injection?

The historic litigation risk centered on Pfizer’s fluconazole patents before generic entry. That risk has largely ended. There is no current, broad patent dispute that materially protects the standard fluconazole-in-dextrose 5% market.

Settlement agreements involving old fluconazole patents may remain relevant to historical launch dates and damages analysis, but they do not generally prevent current ANDA competition. Modern disputes are more likely to involve manufacturing quality, labeling, supply contracts, false advertising or product liability than core patent validity.

When does fluconazole lose exclusivity?

Fluconazole lost meaningful U.S. market exclusivity years ago. The original compound patent and FDA exclusivity periods expired before the current generic hospital market developed. Current suppliers compete under ANDA approvals without a broad period of compound or formulation exclusivity.

The product therefore has:

• No active new chemical entity exclusivity.
• No practical compound-patent barrier.
• Low risk from Paragraph IV challenges to the basic product.
• Potentially narrow protection for later innovations, if separately patented and listed.
• Commercial protection only through contracts, capacity and supply reliability.

What is the outlook for fluconazole injection through 2030?

The product should remain a stable hospital generic with modest unit growth and limited pricing power. The highest-growth regions are likely to be emerging markets where hospital infrastructure and access to parenteral antifungals are expanding. Developed markets will remain highly competitive and tender-driven.

Revenue exposure for manufacturers will depend on portfolio scale. A company with a broad injectable portfolio can use fluconazole to support hospital-account access, but fluconazole alone is unlikely to be a major growth asset. Product withdrawals or shortages could produce temporary price increases, but those gains would not represent durable market expansion.

Generic launch scenarios

Scenario	Expected outcome
New manufacturer enters with FDA-compliant premixed bags	Wins share through contract pricing or supply assurance
Existing supplier adds 100 mg, 200 mg or 400 mg bag sizes	Improves contracting flexibility and hospital formulary coverage
Manufacturer relies on concentrate rather than premixed bags	Lower packaging complexity but weaker convenience proposition
Supplier experiences warning letter or sterile-manufacturing disruption	Rapid loss of hospital contracts and shortage-related regulatory scrutiny
Supplier obtains dual-site manufacturing	Better positioning in tenders and shortage-sensitive accounts

Key Takeaways

• Fluconazole in dextrose 5% is a mature generic intravenous antifungal product.
• The usual concentration is 2 mg/mL in ready-to-use plastic bags.
• The product has no meaningful remaining U.S. compound-patent protection.
• Paragraph IV and patent-litigation risk are low for the standard presentation.
• Clinical demand is supported by candidiasis, cryptococcosis, oncology, transplant and intensive-care use.
• Echinocandins limit initial-treatment demand, while oral fluconazole limits continued IV use.
• The global injectable market is likely in the low hundreds of millions of dollars annually.
• Base-case 2024-2030 unit growth is approximately 2%-3%, with value growth near flat to low single digits.
• Manufacturing quality, supply continuity and hospital contracting are stronger competitive barriers than intellectual property.
• Fluconazole remains commercially relevant as a low-cost, susceptible-isolate therapy and oral step-down option.

FAQs

Is fluconazole in dextrose 5% the same as Diflucan IV?

It contains the same active ingredient and uses a comparable intravenous presentation, but generic products are marketed by different manufacturers and may have different container, labeling and packaging specifications.

Does fluconazole injection treat Candida auris?

Fluconazole should not be assumed to treat Candida auris because resistance is common. Susceptibility testing and current infectious-disease guidance are required for treatment selection.[5]

Can hospitals substitute oral fluconazole for the dextrose bag?

Yes, when the patient can absorb oral medication and clinical status permits. High oral bioavailability makes intravenous-to-oral conversion an important source of IV volume reduction.

Are fluconazole bags protected by formulation patents?

The standard fluconazole-in-dextrose 5% presentation has no broadly blocking formulation patent position comparable to a newly launched specialty drug. Container and manufacturing know-how may remain proprietary without preventing generic competition.

Is fluconazole injection a biosimilar product?

No. Fluconazole is a chemically synthesized small molecule. Injectable generics are approved through the ANDA pathway, not the FDA biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2023). Fluconazole injection prescribing information. FDA.

2. Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., Zaoutis, T. E., & Sobel, J. D. (2016). Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 62(4), e1-e50.

3. World Health Organization. (2022). Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. WHO.

4. U.S. Patent No. 4,404,216. (1983). Antifungal 1,3-bis(triazol-1-yl)-2-propanol derivatives. United States Patent and Trademark Office.

5. Centers for Disease Control and Prevention. (2024). Clinical overview of Candida auris. CDC.